speb/financial-data huggingface dataset:
SYRE balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 715236000.00
SYRE income_statement (annual, 2025-12-31) — Total Expenses: 219562000.00
SYRE income_statement (quarterly, 2025-12-31) — Total Expenses: 57172000.00
SYRE balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 62545000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 62545000.00
SYRE balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 0.00
SYRE balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 0.00
SYRE balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 3860000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 3860000.00
SYRE income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -209562000.00
SYRE income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -57172000.00
SYRE income_statement (annual, 2025-12-31) — Total Unusual Items: 10000000.00
SYRE income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
SYRE income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: 10000000.00
SYRE income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
SYRE balance_sheet (annual, 2025-12-31) — Working Capital: 719096000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Working Capital: 719096000.00
SYRE income_statement (quarterly, 2026-03-31) — +Operating Expense: 75641000.00
SYRE income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
SYRE balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 5692000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1712383000.00
SYRE cash_flow (quarterly, 2026-03-31) — Amortization Of Securities: -2059000.00
SYRE income_statement (quarterly, 2026-03-31) — Basic Average Shares: 78548709.00
SYRE income_statement (quarterly, 2026-03-31) — Basic EPS: -0.74
SYRE cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 85721000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Capital Stock: 155835000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 97185000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 741467000.00
SYRE cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 12255000.00
SYRE cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 56581000.00
SYRE cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -57372000.00
SYRE cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -3176000.00
SYRE cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: 3653000.00
SYRE cash_flow (quarterly, 2026-03-31) — Change In Payable: -3176000.00
SYRE cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 477000.00
SYRE cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -233000.00
SYRE cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 244000.00
SYRE cash_flow (quarterly, 2026-03-31) — Changes In Cash: 11464000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Common Stock: 15000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 514991000.00
SYRE cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 9750000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 24093000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Current Assets: 763953000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 85162000.00
SYRE income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 78548709.00
SYRE income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.74
SYRE income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -69005000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Dueto Related Parties Current: 50000.00
SYRE income_statement (quarterly, 2026-03-31) — EBIT: -75641000.00
SYRE income_statement (quarterly, 2026-03-31) — EBITDA: -75641000.00
SYRE cash_flow (quarterly, 2026-03-31) — End Cash Position: 97185000.00
SYRE cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 12255000.00
SYRE cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -57372000.00
SYRE cash_flow (quarterly, 2026-03-31) — Gain Loss On Sale Of PPE: -30000000.00
SYRE income_statement (quarterly, 2026-03-31) — Gain On Sale Of Ppe: 30000000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -767000.00
SYRE income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 15230000.00
SYRE income_statement (quarterly, 2026-03-31) — Interest Income: 6995000.00
SYRE income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 6995000.00
SYRE cash_flow (quarterly, 2026-03-31) — Interest Received Cfo: 372000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Invested Capital: 514991000.00
SYRE cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 56581000.00
SYRE cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 9750000.00
SYRE cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 9750000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Income: -69005000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -69005000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -69005000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -69005000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -69005000.00
SYRE cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -69005000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -69005000.00
SYRE cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: 30000000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Interest Income: 6995000.00
SYRE cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 26581000.00
SYRE income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 6995000.00
SYRE cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -171000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 670811000.00
SYRE income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -105641000.00
SYRE income_statement (quarterly, 2026-03-31) — Normalized Income: -99005000.00
SYRE cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -57372000.00
SYRE cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -30000000.00
SYRE income_statement (quarterly, 2026-03-31) — Operating Income: -75641000.00
SYRE income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
SYRE balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 78839858.00
SYRE balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 22486000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 50260000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -767000.00
SYRE income_statement (quarterly, 2026-03-31) — Other Gand A: 15230000.00
SYRE income_statement (quarterly, 2026-03-31) — Other Income Expense: -359000.00
SYRE cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 30270000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 7980000.00
SYRE income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -30359000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 644282000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Payables: 5742000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 29835000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 5067000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 155820000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Preferred Stock Equity: 155820000.00
SYRE income_statement (quarterly, 2026-03-31) — Pretax Income: -69005000.00
SYRE cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 2676000.00
SYRE cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -81167000.00
SYRE income_statement (quarterly, 2026-03-31) — Research And Development: 60411000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -1196640000.00
SYRE cash_flow (quarterly, 2026-03-31) — Sale Of Intangibles: 30000000.00
SYRE cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 107748000.00
SYRE income_statement (quarterly, 2026-03-31) — Selling General And Administration: 15230000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Share Issued: 78839858.00
SYRE income_statement (quarterly, 2026-03-31) — Special Income Charges: 30000000.00
SYRE cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 12806000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 670811000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 514991000.00
SYRE income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
SYRE income_statement (quarterly, 2026-03-31) — Tax Provision: 0.00
SYRE income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
SYRE balance_sheet (quarterly, 2026-03-31) — Total Assets: 763953000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 670811000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 670811000.00
SYRE income_statement (quarterly, 2026-03-31) — Total Expenses: 75641000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 93142000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 0.00
SYRE balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 7980000.00
SYRE income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -45641000.00
SYRE income_statement (quarterly, 2026-03-31) — Total Unusual Items: 30000000.00
SYRE income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 30000000.00
SYRE balance_sheet (quarterly, 2026-03-31) — Working Capital: 678791000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -566340000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 2524910000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -59500000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Amortization: 13760000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 176229137.00
SYRMA.NS income_statement (annual, 2022-03-31) — Basic EPS: 3.15
SYRMA.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 347500000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 192020000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 142090000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 176229137.00
SYRMA.NS income_statement (annual, 2022-03-31) — Diluted EPS: 3.15
SYRMA.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 23690000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 200040000.00
SYRMA.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 159920000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 2781840000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Hedging Assets Current: 390000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Interest Income: 16240000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 16240000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Investment Properties: 4130000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Investmentsin Associatesat Cost: 2190000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 636200000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 2190000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 1695860000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 18430000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 69600000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 48520000.00
SYRMA.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: 259680000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Other Payable: 175200000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 59000000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Other Special Charges: -9310000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 291030000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 2069370000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 7640000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 7640000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Research And Development: 12760000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 34970000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 1462170000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 133170000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 293090000.00
SYRMA.NS cash_flow (annual, 2022-03-31) — Short Term Debt Issuance: 1036140000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Taxes Receivable: 294670000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 33880000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Tradeand Other Payables Non Current: 14630000.00
SYRMA.NS balance_sheet (annual, 2022-03-31) — Work In Process: 643590000.00
SYRMA.NS income_statement (annual, 2022-03-31) — Write Off: 7320000.00
SYRMA.NS income_statement (annual, 2023-03-31) — +Operating Expense: 2887650000.00
SYRMA.NS income_statement (annual, 2023-03-31) — +Total Revenue: 20098240000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 4894770000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 4022250000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -868390000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 10654300000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -70650000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Amortization: 20760000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 20760000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 49560000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 176777842.00
SYRMA.NS income_statement (annual, 2023-03-31) — Basic EPS: 6.75
SYRMA.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 334110000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 776960000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -1183960000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Capital Expenditure Reported: -1183960000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 278860000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 1767780000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 464900000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 1245340000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 46030000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 418870000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -2957310000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -432440000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -141910000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Change In Payable: 2496540000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -1282690000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -2299860000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 119670000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Common Stock: 1767780000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 15402780000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 8760010000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Common Stock Payments: -326120000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 219230000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 15587330000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Current Assets: 12277940000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 32220000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Current Debt: 2598530000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 2630750000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 8613520000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 41590000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Depreciation: 291230000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 311990000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 311990000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 291230000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 176777842.00
SYRMA.NS income_statement (annual, 2023-03-31) — Diluted EPS: 6.75
SYRMA.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 1193200000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Dividends Received Cfi: 0.00
SYRMA.NS income_statement (annual, 2023-03-31) — EBIT: 1991960000.00
SYRMA.NS income_statement (annual, 2023-03-31) — EBITDA: 2303950000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 11120000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — End Cash Position: 464900000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 10240000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 9679600000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 474860000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -1886720000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -25500000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 500000.00
SYRMA.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 174740000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Goodwill: 1181850000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 1267520000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 4092900000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 5193410000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Gross Profit: 4510910000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 0.00
SYRMA.NS income_statement (annual, 2023-03-31) — Interest Expense: 204650000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 204650000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Interest Income: 323480000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 323480000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -192170000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 287580000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Inventory: 5874370000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 18871160000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -8857170000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Investment Properties: 0.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 59800000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Investmentsin Associatesat Cost: 160000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 8760010000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 1546760000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 638890000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 246640000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 869850000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 1116490000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 856980000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -24090000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 160000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 2914120000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 26150000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Minority Interests: -37560000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: -196330000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 8433890000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Net Debt: 3003480000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -40450000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Income: 1193200000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 1193200000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 1230760000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 1193200000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 1193200000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 1787310000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 1230760000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Interest Income: 66250000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -7766330000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 1522670000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 832890000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 66250000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: -39750000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Net PPE: 4325020000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: 1870000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 689780000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 14135260000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 16430000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 0.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 137550000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 92050000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 105410000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 2287830000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Normalized Income: 1182096626.33
SYRMA.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: -702760000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Operating Income: 1623260000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Operating Revenue: 20098240000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 176777842.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 214430000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 61510000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 85670000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -112070000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: -50000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 8430000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 606500000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Payable: 440090000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Properties: 644210000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 70370000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 780440000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Other Special Charges: -990000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Payables: 5501530000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 246850000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Pretax Income: 1787310000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 8200000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -196330000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -7779920000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 4678480000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 15587330000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 311990000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 6560000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 6560000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -24090000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -326120000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Research And Development: 16710000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 79390000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 2846740000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 13590000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 1870000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 144830000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 319570000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Share Issued: 176777842.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Short Term Debt Issuance: 689780000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Special Income Charges: -7730000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 57170000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 15402780000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 14135260000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 5016626.33
SYRMA.NS income_statement (annual, 2023-03-31) — Tax Provision: 556220000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.31
SYRMA.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 739370000.00
SYRMA.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -397300000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Assets: 25425550000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 16272630000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Debt: 3747240000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 15428930000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Total Expenses: 18474980000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 9996620000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 13147610000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 1383100000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 52580000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 166670000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 16120000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 16120000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 20580000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Work In Process: 721030000.00
SYRMA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 3664420000.00
SYRMA.NS income_statement (annual, 2023-03-31) — Write Off: 8720000.00
SYRMA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 4565050000.00
SYRMA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 31302650000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 12230940000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 9301460000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -1359750000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 10589290000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -139750000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Amortization: 39590000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 39590000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 53260000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 177095444.00
SYRMA.NS income_statement (annual, 2024-03-31) — Basic EPS: 6.06
SYRMA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 464900000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1851320000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -3376540000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure Reported: -3376540000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 535780000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 1774270000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 783840000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 1141140000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -265160000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 8180000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 775660000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -3776210000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -1156870000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -9160000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Change In Payable: 7269650000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -5143660000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -2807440000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 128660000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 1774270000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 16126080000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 80000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: -88150000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 221140000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 25223560000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 22761920000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 69520000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 5118290000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 5187810000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 18447440000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 41820000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Depreciation: 475260000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 514850000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 514850000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 475260000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 178357981.00
SYRMA.NS income_statement (annual, 2024-03-31) — Diluted EPS: 6.02
SYRMA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 1073280000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 2590000.00
SYRMA.NS income_statement (annual, 2024-03-31) — EBIT: 2037850000.00
SYRMA.NS income_statement (annual, 2024-03-31) — EBITDA: 2552700000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 8290000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 783840000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 10590000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 1502740000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 1006790000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -4467850000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -29240000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 5080000.00
SYRMA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 322270000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Goodwill: 3221030000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 3450170000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 9441210000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 8946760000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Gross Profit: 6079090000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Interest Expense: 373440000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 373440000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Interest Income: 335890000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 335890000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -361700000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 358410000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Inventory: 10042570000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 21889180000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -282770000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Investment Properties: 0.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 63850000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 160000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 80000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 2320350000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 1374100000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 466260000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 644810000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 1111070000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 0.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -32660000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 160000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 5095420000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 644210000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Minority Interests: -170120000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -2300260000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -88070000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Net Debt: 4979260000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -68890000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Income: 1073280000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 1073280000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 1243400000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 1073280000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 1073280000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 1664410000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 1243400000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Interest Income: -77180000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 5027390000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 2287690000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -32660000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -77180000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: 9220000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: -1400000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 7587010000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: 7040000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 2320350000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 12675910000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 14420000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 12400000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 176220000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 132230000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 131840000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 2532250000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Normalized Income: 1058002796.67
SYRMA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: -1091310000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Operating Income: 1514040000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 31302650000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 177427081.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Other Cash Adjustment Outside Changein Cash: 181990000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 240000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 522390000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 46150000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 229140000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 69180000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 30000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 35760000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 36080000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 843960000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 448820000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 404780000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 1944560000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 357300000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Other Special Charges: 18590000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Payables: 12754540000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 252070000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Pretax Income: 1664410000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 69080000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -2300260000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: 0.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 7629250000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 25223560000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 514850000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 7260000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 7260000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -32660000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -88150000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Research And Development: 15440000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 79880000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 3684960000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 5027390000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 7040000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 175900000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 498170000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 177585081.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 2320350000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Special Income Charges: -19840000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 29920000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 16126080000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 12675910000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 5172796.67
SYRMA.NS income_statement (annual, 2024-03-31) — Tax Provision: 421010000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.25
SYRMA.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 1631490000.00
SYRMA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -539510000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 36894260000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 16770890000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 6298880000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 16770290000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Total Expenses: 29788610000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 20123970000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 14132340000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 1676530000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 39630000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 74780000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 20450000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 20450000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Tradeand Other Payables Non Current: 24430000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 158000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Work In Process: 1406530000.00
SYRMA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 4314480000.00
SYRMA.NS income_statement (annual, 2024-03-31) — Write Off: 1250000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 14610070000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 10503670000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 167340000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 530030000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 1774270000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 676420000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 4512800000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 1774270000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 16433200000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 454240000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 27097190000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 79930000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 5309290000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 5389220000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 20763150000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 39460000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 3221030000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 3460570000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 8711970000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 10122500000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 22461450000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 167340000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 450100000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 718960000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 1169060000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 688540000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 5351830000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 8711970000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 12972630000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 9250000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 159180000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Pension And Other Postretirement Benefit Plans: 171540000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 177427081.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 1958220000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 481240000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 14658930000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 239540000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 57430000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 58400000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 8257730000.00
SYRMA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 3836380000.00